Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.57 |
| ▸ | FAAH | O00519 | 4/20 | 0.57 |
| ▸ | LTA4H | P09960 | 3/20 | 0.55 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.55 |
| ▸ | CDK4 | P11802 | 5/20 | 0.53 |
| ▸ | CCND1 | P24385 | 5/20 | 0.53 |
| ▸ | SNCA | P37840 | 1/20 | 0.51 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7334188 | 0.93 | TRPV1 (0.65) | TRPV1FAAHLTA4HPLA2G2ACDK4 | |
| SCHEMBL7307246 | 0.86 | FAAH (0.56) | TRPV1FAAHLTA4HPLA2G2ATRPM8 | |
| SCHEMBL8807970 | 0.84 | HTR7 (0.57) | TRPV1FAAHIDO1MEN1RAB9A | |
| SCHEMBL21564239 | 0.82 | IDO1 (0.60) | TRPV1FAAHLTA4HPLA2G2ACDK4 | |
| SCHEMBL5745010 | 0.81 | MEN1 (0.67) | FAAHCDK4CCND1MEN1NPC1 | |
| SCHEMBL8613795 | 0.80 | TRPV1 (0.55) | TRPV1FAAHIDO1MEN1RAB9A | |
| SCHEMBL31077788 | 0.80 | TRPV1 (0.70) | TRPV1IDO1MEN1KMT2A | |
| SCHEMBL798165 | 0.80 | TRPV1 (0.70) | TRPV1IDO1MEN1KMT2A | |
| SCHEMBL6577939 | 0.79 | FAAH (0.53) | TRPV1FAAHLTA4HPLA2G2ATRPM8 | |
| SCHEMBL2544150 | 0.79 | HPGD (0.55) | TRPV1FAAHIDO1MEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020004198-A1 | Novel anti-infectives | SMITHKLINE BEECHAM CORPORATION | 2002-01-10 | — | — | US | disclosed |
| US-20010007877-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION | 2001-07-12 | — | — | US | disclosed |
| WO-2001034146-A1 | NOVEL ANTI-INFECTIVES | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010007877-A1 | NOVEL ANTI-INFECTIVES | CTSL, MMP8, SERPINB1 | TRPV1 2884/4885FAAH 3191/4885LTA4H 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.